Indivior Pharmaceuticals, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

INDV$36.28+2.6%Stored close · as of Nov 2, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Financial Statements and Supplementary Data

Consolidated Statements of Operations

(In millions, except per share data)

	Twelve Months Ended December 31,
	2025	2024	2023
Net revenue	$1,239	$1,188	$1,093
Cost of sales	246	231	174
Gross profit	994	957	919
Operating expenses:
Selling, general and administrative	634	612	565
Research and development	97	107	116
Acquired in-process research and development	—	1	162
Litigation settlement	3	195	239
Other operating (income) expense, net	(3)	4	(9)
Operating income (loss)	262	38	(152)
Other (income) and expenses:
Interest income	(22)	(23)	(43)
Interest expense	45	41	35
Income (loss) before income taxes	239	20	(145)
Income tax expense (benefit)	29	13	(19)
Net income (loss)	$210	$7	$(126)
Earnings (loss) per share
Basic	$1.68	$0.05	$(0.92)
Diluted	$1.64	$0.05	$(0.92)
Shares used in computing earnings (loss) per share
Basic	125	132	137
Diluted	128	133	137

Consolidated Statements of Comprehensive Income (Loss)

	Twelve Months Ended December 31,
	2025	2024	2023
Net income (loss)	$210	$7	$(126)
Other comprehensive income, net of tax
Foreign currency translation	6	(6)	2
Other comprehensive income (loss)	6	(6)	2
Total comprehensive income (loss)	$216	$1	$(124)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.